The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch-Reference-Cited by-同舟云学术

The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch

Published:2023-09-21 Issue:5 Volume:20 Page:271-285
ISSN:1548-3568
Container-title:Current HIV/AIDS Reports
language:en
Short-container-title:Curr HIV/AIDS Rep

Author:

Goebel Melanie C.^ORCID,Guajardo Emmanuel,Giordano Thomas P.,Patel Shital M.

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Virology

Link

https://link.springer.com/content/pdf/10.1007/s11904-023-00665-x.pdf

Reference89 articles.

1. Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13(11):e1002183. https://doi.org/10.1371/journal.pmed.1002183.

2. Centers for Disease Control and Prevention: Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html (2021). Accessed February 10, 2023.

3. Centers for Disease Control and Prevention. Ending the HIV Epidemic in the U.S. (EHE). https://www.cdc.gov/endhiv/treat.html. Accessed 10 Feb 2023.

4. ViiV Healthcare: Cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension (Cabenuva) [package insert]. U.S. Food and Drug Administration Website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006lbl.pdf Accessed April 13, 2023.

5. Hodge D, Back DJ, Gibbons S, Khoo SH, Marzolini C. Pharmacokinetics and drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet. 2021;60(7):835–53. https://doi.org/10.1007/s40262-021-01005-1.